Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10885691 | 1.00 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL23925241 | 1.00 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL21195733 | 0.84 | TSHR (0.33) | PDE4ATSHRCYP2C9 | |
| SCHEMBL21195712 | 0.84 | TSHR (0.33) | PDE4ATSHRCYP2C9 | |
| SCHEMBL6258700 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL645759 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL19384838 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL1143744 | 0.79 | PDE4A (0.39) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL5029667 | 0.78 | PDE4A (0.38) | PDE4ATSHRCYP2C9ALDH1A1 | |
| SCHEMBL23923262 | 0.76 | PDE4A (0.36) | PDE4ATSHRCYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8778892-B2 | Compounds and methods for treatment of solid tumors | B & G PARTNERS, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120295284-A1 | Fluorecent Saccharide Conjugates | B&G PARTNERS, LLC | 2012-11-22 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100240878-A1 | Fluorescent saccharide conjugates | B&G PARTNERS, LLC | 2010-09-23 | — | — | US | disclosed |
| US-20090239820-A1 | Compounds and methods for treatment of solid tumors | BARBEAU DONALD L | 2009-09-24 | — | — | US | disclosed |
| US-5952313-A | COMPOSITION FOR ANTAGONIZING GRAM NEGATIVE BACTERIAL ENDOTOXIC ACTIVITY, COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND AN ANTAGONIZING AMOUNT OF A LIPOPOLYSACCHARIDE FROM A RHIZOBIUM ETLI; TREATMENT OF SEPTIC SHOCK OR TOXIC SHOCK | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0824538-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5648343-A | ADMINISTERING A LIPID | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1996035700-A9 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | — | 1997-02-13 | — | — | WO | disclosed |
| EP-0748327-A1 | STRUCTURE OF A NOVEL LIPID A AND METHODS UTILIZING SAME | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996035700-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1995023156-A1 | STRUCTURE OF A NOVEL LIPID A AND METHODS UTILIZING SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240878-A1 | Fluorescent saccharide conjugates | CD44, FUT6, SIGLEC7 | PDE4A 4795/4885TSHR 3233/4885CYP2C9 4834/4885 |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | PDE4A 2231/4885TSHR 2588/4885CYP2C9 2457/4885 |
| US-20090239820-A1 | Compounds and methods for treatment of solid tumors | VHL, HCAR1, HCAR2 | PDE4A 2124/4885TSHR 1019/4885CYP2C9 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.